April 9, 2026·5 min read·primer, administration, fundamentals
Subcutaneous vs intramuscular injection — routes and pharmacokinetics
Absorption kinetics, needle sizing, injection sites, and when to choose each route.
Absorption kinetics, needle sizing, injection sites, and when to choose each route.
Two routes dominate research peptide administration: subcutaneous (SC) and intramuscular (IM). They're mechanically simple but pharmacologically different. Where you inject changes how fast the peptide absorbs, how long it circulates, and whether you get the dose-response curve described in the literature. This is why understanding your peptide's original study and how it was administered is crucial to setting realistic expectations.
Subcutaneous injection places the needle below the dermis, into adipose (fat) tissue. The depot of peptide sits in a space with limited blood flow compared to muscle, so absorption is slow — typically hours for the peptide to reach peak plasma concentration. A GLP-1 injected subcutaneously at 8 a.m. won't peak until afternoon or evening.
Needle sizing is small. 29G or 31G needles are standard, with lengths of 4–8 mm (5/16 to 5/16 inch). These are the same sizes as insulin needles. They cause minimal tissue trauma, inject painlessly for most users, and are easy to carry.
Common injection sites are the abdomen (avoiding a 2-inch radius around the umbilicus due to nerve and vascular density), the lateral thigh (vastus lateralis — the outer front of the thigh), and the upper outer arm (deltoid region). Some people rotate systematically (abdomen one week, thigh the next) to distribute the irritation and avoid lipohypertrophy — the formation of lumpy, scarred fat tissue from repeated injection in the same spot.
The pharmacokinetics of most research peptides are designed around SC dosing. GLP-1 agonists, GH secretagogues, thymosin alpha 1, and healing peptides are all characterized in the literature under SC administration. If the published studies used SC, your baseline expectation for the dose-response curve, timing, and side effects assumes SC. IM administration changes the curve. This is why reading the original literature carefully — including the administration route — is critical before deciding on your own approach.
Intramuscular injection places the needle into the muscle belly itself — usually the ventrogluteal (hip), deltoid (shoulder), or vastus lateralis (outer thigh). Muscle has higher blood flow than adipose, so absorption is faster — onset to peak can be minutes to 1–2 hours, compared to hours for SC.
Needle sizing is larger. 22G to 25G is typical, with lengths of 25–38 mm (1–1.5 inches) to ensure you reach muscle rather than subcutaneous tissue. The larger gauge and longer length mean more tissue trauma. For most people, IM injections are more painful than SC and leave soreness for 24–48 hours.
The faster absorption creates a higher peak plasma concentration (higher Cmax) for the same dose. If you're accustomed to an SC dose, switching to IM will feel more potent because the drug reaches the CNS and peripheral receptors faster.
IM is chosen when pharmacokinetics require rapid onset. Some GH secretagogues, for instance, work partially through a time-dependent mechanism — the faster the CNS exposure, the larger the growth-hormone pulse. Others use IM when the literature specifically characterized it that way, or when repeated SC injections in the same area cause unacceptable irritation.
A few peptides cause localized inflammation when injected SC (redness, swelling, minor irritation at the injection site). IM may sidestep this if the irritant is purely local and not systemic. That said, IM is not a fix-all. If the peptide causes systemic GI side effects (nausea, early satiety), changing the route won't help.
Repeated injections in the same spot can trigger an inflammatory response and lead to lipohypertrophy — hypertrophied (enlarged) fat cells and scarring that feel like a firm lump under the skin. It's not dangerous, but it's uncomfortable, unsightly, and the lump can absorb peptides differently (unpredictably slower), throwing off your dosing consistency.
Rotate sites systematically. Abdomen, thigh, arm — cycle through them week to week. If doing multiple weekly injections, use a different site each time rather than all three in the same area on the same day.
IM injections sometimes use a modified technique called the Z-track method. After inserting the needle, you pull the skin taut to one side (displacing it 1–2 cm), inject the dose, wait 10 seconds, then release. This creates a "Z" path that the peptide molecules have to traverse backward through, theoretically minimizing backtrack along the needle tract into subcutaneous tissue and reducing local irritation. It's standard in pharmaceutical nursing but less common in self-administered research contexts.
After injection, needles go into a sharps container — a puncture-resistant plastic bin designed to hold used needles. Never recap a needle single-handed; if you must recap, use a one-handed "scoop" technique where you lay the cap flat on the table, push the needle in, and pick up the capped syringe. Better yet, don't recap at all — just drop it into sharps immediately.
Once the sharps container is 2/3 full, seal it and dispose of it per local regulations. Many cities allow household sharps containers to be disposed of in regular trash (sealed). Some pharmacies accept them for free. Check your local guidelines.